CD274 and neoplasm: In several tumor models, BET-bromodomain inhibitors such as JQ1 also restored tumor immunogenicity by increasing MHC-I and reducing PD-L1 expression in tumor cells leading to their enhanced recognition by T cells (182–184) (Figure 7C).